Navigation Links
Immucor Appoints Chief Operating Officer

NORCROSS, Ga., July 16 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that Geoffrey S. Crouse has been named Vice President and Chief Operating Officer.

In this newly created position, Mr. Crouse will have worldwide responsibility for manufacturing and distribution as well as sales, marketing and customer service. Mr. Crouse will report to Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer.

Mr. Crouse previously served as vice president of the life sciences business at Millipore Corporation, a NYSE-traded provider of technologies, tools and services for the global life science industry. In this role, he led the Life Science Strategic Business Unit, a global laboratory consumables and reagents business, and held responsibility for manufacturing, research and development, sales and marketing. During his tenure, Mr. Crouse improved manufacturing operations, led multiple acquisitions and integrations while increasing sales and profitability for the business unit.

"We are pleased to strengthen our management team with the addition of Geoff," stated Dr. De Chirico. "His experience and results-oriented track record will enhance our efforts to improve transfusion medicine through automation. Our commitment to improving blood bank operations and patient safety benefits our customers, employees and shareholders."

Mr. Crouse's experience includes various leadership roles in both the U.S. and internationally. Prior to joining Millipore, Mr. Crouse worked at Roche, a Swiss Exchange-traded leader in the pharmaceuticals and diagnostics industries, where he most recently led market development and government affairs for the diagnostics division based in Basil, Switzerland.

Mr. Crouse holds a Masters of Business and a Masters of Public Health from the University of California, Berkeley as well as a Bachelor of Arts degree from Boston College.

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at

SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department
2. Immucor to Announce Fiscal Fourth Quarter Financial Results on Thursday, July 23, 2009
3. Immucor Announces Fiscal Year 2010 Guidance
4. Immucor to Announce Fiscal 2010 Guidance on Monday, June 1, 2009
5. Immucor to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
6. Immucor Receives Subpoena From Department of Justice
7. Immucor Announces Fiscal Third Quarter Results
8. Immucor Announces New Vice President, Operations
9. Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance
10. Immucor Closes BioArray Acquisition
11. Immucor Schedules Fiscal 2009 Guidance Call
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... Ruth Pearson ... brutal lupus flare-up. Unable to walk without assistance and quickly losing hope of recovering ... then a miracle happened. , Pearson was attending a women’s retreat when she experienced ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... 01, 2015 , ... December 1, 2015 -- InstantLabs is ... growing product line of food safety and seafood fraud prevention tools. , The ... allow InstantLabs to offer fast, reliable species identification for the four most popular ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
Breaking Medicine Technology: